Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Michele Maio, Arnaud Scherpereel, Luana Calabrò, +15

The Lancet Oncology

Surgical OncologyMalignant DiseaseRelapsed Malignant MesotheliomaMedicinePlacebo-controlled Phase 2B +6

Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis

Gianluca Masi, E. Vasile, Fotios Loupakis, +17

JNCI Journal of the National Cancer Institute

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

Bristi Basu, Emma Dean, M. Puglisi, +12

Clinical Cancer Research

Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.

Hedy L. Kindler, Arnaud Scherpereel, Luana Calabrò, +16

Journal of Clinical Oncology

Surgical OncologyCancer ManagementImmunologyPathologyImmunotherapy +18

A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.

Víctor Moreno, Richard D. Baird, Kinjal Shah, +15

Journal of Clinical Oncology

Gdc-0941 Plasma ConcentrationsAdvanced Solid TumorsTumor BiologyMagnetic Resonance ImagingHematological Malignancy +15

ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer.

Domenica Lorusso, Nicoletta Colombo, Robert L. Coleman, +17

Journal of Clinical Oncology

Advanced Cervical CancerCervical Cancer ManagementPd-l1–positive RecurrentCervical CancerCancer Therapeutics +13

First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.

Udai Banerji, Emma Dean, Michael V. Gonzalez, +10

Journal of Clinical Oncology

Azd2014 BdBreast OncologySolid TumorsPharmacotherapyTumor Biology +15

A study of motivations and expectations of patients seen in phase 1 oncology clinics

Saoirse Dolly, Eleftheria Kalaitzaki, M. Puglisi, +12

Cancer

ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.

Ignace Vergote, Jalid Sehouli, Vanda Salutari, +15

Journal of Clinical Oncology

Pd-l1 StatusBevacizumab UseOlaparib MaintenanceEpithelial Ovarian CancerMedicine +12

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines

M. Puglisi, P. Thavasu, Andrew N. Stewart, +5

Lung Cancer

Growth-inhibitory EffectsMedicineAkt InhibitionCell DeathCancer Biology +6